Neutralizing gp41 antibodies and their use

Patent metadata

Field	Value
Publication number	US-2016333076-A1
Application number	US-201615226744-A
Country	US
Kind code	A1
Filing date	Aug 2, 2016
Priority date	Nov 7, 2011
Publication date	Nov 17, 2016
Grant date	—

Abstract

Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.

First claim

We claim:

1 . An isolated nucleic acid molecule encoding a human monoclonal antibody, the antibody comprising:
a heavy chain variable region comprising a heavy chain complementarity determining region (HCDR)1, a HCDR2, and a HCDR3 comprising amino acids 26-33, 51-60, and 99-120 of SEQ ID NO: 1, respectively; and a light chain variable region comprising a light chain complementarity determining region (LCDR)1, a LCDR2, and a LCDR3, comprising amino acids 26-31, 49-51, and 88-99 of SEQ ID NO: 2, respectively; wherein the antibody specifically binds gp41 and neutralizes HIV-1.

2 . The isolated nucleic acid molecule of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth as one of SEQ ID NOs: 1, 3, 5, 149, 154, 189-192, 200-201, or 204, and further comprises at most ten amino acid substitutions in framework regions of the heavy chain variable region.

3 . The isolated nucleic acid molecule of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 11, wherein X 1 is Q or R, X 2 is V or A, X 3 is S or Y, and X 4 is T or I.

4 . The isolated nucleic acid molecule of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth as one of SEQ ID NOs: 1, 3, 5, 149, 154, 189-192, 200-201, or 204.

5 . The isolated nucleic acid molecule of claim 1 , wherein the light chain variable region comprises the amino acid sequence set forth as one of SEQ ID NOs: 2, 4, 150-152, or 164-168, and further comprises at most ten amino acid substitutions in framework regions of the light chain variable region.

6 . The isolated nucleic acid molecule of claim 1 , wherein the light chain variable region comprises the amino acid sequence set forth as one of SEQ ID NOs: 2, 4, 150-152, or 164-168.

7 . The isolated nucleic acid molecule of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth as one of SEQ ID NOs: 1, 3, 5, 149, 154, 189-192, 200-201, or 204, and the light chain variable region comprises the amino acid sequence set forth as one of SEQ ID NOs: 2, 4, 150-152, or 164-168.

8 . The isolated nucleic acid molecule of claim 1 , wherein:
the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 154, and the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 152; or the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 192, and the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 152.

9 . The isolated nucleic acid molecule of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 1.

10 . The isolated nucleic acid molecule of claim 1 , wherein the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 2.

11 . The isolated nucleic acid molecule of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 1 and further comprises at most ten amino acid substitutions in framework regions of the heavy chain variable region, and the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 2 and further comprises at most ten amino acid substitutions in framework regions of the light chain variable region.

12 . The isolated nucleic acid molecule of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 1, and the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 2.

13 . The isolated nucleic acid molecule of claim 1 , wherein the antibody is an IgG, IgM or IgA antibody.

14 . The isolated nucleic acid molecule of claim 1 , wherein the antibody is an IgG 1 antibody.

15 . The isolated nucleic acid molecule of claim 12 , wherein the antibody is an IgG 1 antibody.

16 . The isolated nucleic acid molecule of claim 1 , wherein the antibody neutralizes at least 98% of the HIV-1 isolates listed in FIGS. 17C-17F with an inhibitory concentration (IC50) of less than 50 μg/ml.

17 . The isolated nucleic acid molecule of claim 1 , wherein the antibody neutralizes at least 72% of the HIV-1 isolates listed in FIGS. 17C-17F with an inhibitory concentration (IC50) of less than 1 μg/ml.

18 . The isolated nucleic acid molecule of claim 1 , wherein the antibody is a bispecific antibody.

19 . An isolated nucleic acid molecule encoding an antigen binding fragment of a human monoclonal antibody, the antigen binding fragment comprising:
a heavy chain variable region comprising a heavy chain complementarity determining region (HCDR)1, a HCDR2, and a HCDR3 comprising amino acids 26-33, 51-60, and 99-120 of SEQ ID NO: 1, respectively; and a light chain variable region comprising a light chain complementarity determining region (LCDR)1, a LCDR2, and a LCDR3, comprising amino acids 26-31, 49-51, and 88-99 of SEQ ID NO: 2, respectively; wherein the antigen binding fragment specifically binds gp41 and neutralizes HIV-1 infection.

20 . The isolated nucleic acid molecule of claim 19 , wherein the antigen binding fragment is a Fab fragment, a Fab′ fragment, a F(ab)′2 fragment, a single chain Fv protein (scFv), or a disulfide stabilized Fv protein (dsFv).

21 . The isolated nucleic acid molecule of claim 20 , wherein the antigen binding fragment is a Fab fragment.

22 . The isolated nucleic acid molecule of claim 1 , operably linked to a promoter.

23 . An expression vector comprising the isolated nucleic acid molecule of claim 1 .

24 . An expression vector comprising the isolated nucleic acid molecule of claim 12 .

25 . The expression vector of claim 23 , wherein the expression vector is an adeno-associated viral vector.

26 . The expression vector of claim 24 , wherein the expression vector is an adeno-associated viral vector.

27 . A composition comprising:
(a) the nucleic acid molecule of claim 1 ; and (b) a pharmaceutically acceptable carrier.

28 . A kit comprising:
(a) the nucleic acid molecule of claim 1 ; and (b) instructions for using the kit.

Assignees

• Us Health

Inventors

• Connors Mark
• Huang Jinghe
• Laub Leo B
• Kwong Peter
• Nabel Gary
• Mascola John R
• Zhang Baoshan
• Rudicell Rebecca S
• Georgiev Ivelin
• Yang Yongping
• Zhu Jiang
• Ofek Gilad

Classifications

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title

• G01N33/56972

  White blood cells · CPC title

• C07K2317/567

  Framework region [FR] · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title